PMID- 34664513
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 36
IP  - 2
DP  - 2022 Mar
TI  - Efficacy and Safety of Subcutaneous Immunotherapy for Local Allergic Rhinitis: A 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 245-252
LID - 10.1177/19458924211050547 [doi]
AB  - BACKGROUND: Subcutaneous immunotherapy (SCIT) has been used for treating local 
      allergic rhinitis (LAR) patients. However, the clinical efficacy and safety were 
      still questioned. OBJECTIVE: This study was designed to estimate the efficacy and 
      safety of SCIT for treating LAR patients through meta-analysis. METHODS: We 
      systemically searched MEDLINE, Cochrane Library, and Embase publications. 
      Randomized, double-blind, clinical trials for the efficacy and safety of Allergen 
      Immunotherapy (AIT) for LAR were included. A meta-analysis of 4 clinical 
      endpoints (combined symptom and medication scores [CSMS], symptom scores [SS], 
      medication scores [MS] and rhinoconjunctivitis quality of life questionnaire 
      [RQLQ]) and adverse events (AEs)) was performed after bias and heterogeneity 
      assessments. The immunologic response results were summarized. RESULTS: Four RCTs 
      with 134 patients were included. Four studies for analyzing primary outcomes 
      (CSMS, SS, MS) and AEs, three for RQLQ results. The results indicated an 
      important significant difference between SCIT and placebo groups, list as 
      follows: CSMS (SMD = -2.42, 95% CI: -3.60 to -1.25, P < .0001), SS (SMD = -2.08, 
      95% CI -3.68 to -0.48, P = .01), MS (SMD = -1.43, 95% CI: -2.65 to -0.21, 
      P = 0.02), RQLQ (SMD = -0.70, 95% CI -1.29 to -0.12, P = .02), Local AEs 
      (RR = 4.13, 95% CI 1.08 to 15.77, P = .04). For immunologic response, 
      significantly increased serum sIgG4 levels and improvements of allergen tolerance 
      was observed after SCIT. CONCLUSIONS: Our meta-analysis suggests that SCIT has a 
      significant effect on improving symptoms and reducing medicine consumption for 
      LAR patients. Larger and multicenter clinical trials are needed to clarify the 
      safety and long-term efficacy.
FAU - Zhu, Wanting
AU  - Zhu W
AUID- ORCID: 0000-0001-8692-3647
AD  - Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, 
      12443Huazhong University of Science and Technology, Wuhan, China.
FAU - Gao, Pei
AU  - Gao P
AD  - Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, 
      12443Huazhong University of Science and Technology, Wuhan, China.
FAU - Zhang, Qidi
AU  - Zhang Q
AD  - Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, 
      12443Huazhong University of Science and Technology, Wuhan, China.
FAU - Chen, Jianjun
AU  - Chen J
AD  - Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, 
      12443Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211019
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
SB  - IM
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Multicenter Studies as Topic
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Rhinitis, Allergic/therapy
OTO - NOTNLM
OT  - allergen immunotherapy
OT  - clinical effects
OT  - local allergic rhinitis
OT  - meta-analysis
OT  - subcutaneous immunotherapy
EDAT- 2021/10/20 06:00
MHDA- 2022/02/04 06:00
CRDT- 2021/10/19 08:39
PHST- 2021/10/20 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2021/10/19 08:39 [entrez]
AID - 10.1177/19458924211050547 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2022 Mar;36(2):245-252. doi: 10.1177/19458924211050547. Epub 
      2021 Oct 19.